IntroductIon
Embryonic stem (ES) cells have great potential for cell therapy against genetic disorders, as such cells can contribute to the specialized function of any tissue. 1, 2 However, one potential problem using ES cells to treat genetic disorders is host immunorejection of the transplanted cells. Although ES cells for gene therapy may be created for a patient using the nuclear transfer technique, many ethical concerns are associated with this practice. 3, 4 Conversely, induced pluripotent stem (iPS) cells can be generated from the tissues of the individual with defined factors. [5] [6] [7] Gene and cell therapies with iPS cells will thus offer advantages over nuclear transfer ES cell-mediated gene therapy with respect to ethical problems, as well as providing a genetic match with the patient and so decreasing the likelihood of immunorejection.
Homologous recombination has been used for the gene restoration of various genetic defects in ES or iPS cells using one's own genetic information. 8, 9 However, gene defects with unknown sites of mutation and those involving large deletions cannot be restored by homologous recombination. 10 Duchenne muscular dystrophy (DMD) is caused by dysfunction of the dystrophin gene. [11] [12] [13] [14] [15] As some DMD patients show a large deletion in the DMD gene, these defects cannot be restored by homologous recombination or exon-skipping approaches. Although several vectors have been developed for DMD gene therapy, no episomal vector containing the entire dystrophin genomic region has been reported, due to the extremely large size of this region (2.4 megabases). 16 Human artificial chromosome (HAC) offers several advantages as gene therapy vector, including stable episomal maintenance that avoids insertional mutations and the ability to carry large gene inserts including the associated regulatory elements. [17] [18] [19] [20] [21] [22] [23] We therefore recently developed a HAC vector containing an entire dystrophin genome for DMD gene therapy. 21 In this study, we established a HAC-mediated genomic transfer system as a paradigm for the treatment of a genetic disorder such as DMD by combining patient-derived iPS cells with a HAC vector containing the normal version of a defective gene.
results characterization of iPs cells from mdx mice
First, we attempted genetic correction of iPS cells derived from mdx mouse, as a model for DMD (Figure 1) . The mdx-iPS cells were induced from mdx mouse embryonic fibroblasts by retroviral infection of the three factors including Klf4, Sox2, and Oct4. Transduced fibroblasts from the mdx mice gave rise to ES celllike colonies, and these colonies were isolated based on morphological criteria. Most mdx-iPS cells were positive for ES cell This DYS-HAC, which contains a visualization marker gene GFP and suicide gene TK, was transferred to the two independent mdxiPS clones via microcell-mediated chromosome transfer (MMCT). Eight GFP + clones were selected and examined in the following experiments (Figure 2a) . PCR analysis using primers for the detection of the DYS-HAC showed that six of the eight clones contained the intact dystrophin region in the HAC (Figure 2b) . Reverse transcription (RT)-PCR analysis showed expression of dystrophin from the DYS-HAC was detected in six clones with the intact genomic dystrophin, whereas enhanced green fluorescent protein (EGFP) was expressed in all the clones examined (Figure 2d) . Fluorescence in situ hybridization (FISH) analyses showed that the DYS-HAC was present as an individual chromosome in the mdx-iPS cells (Figure 2c) . These results show that the DYS-HAC can be transferred to mouse iPS cells at a comparable efficiency to that in mouse ES cells. 21 To test the stemness of the iPS cells, RT-PCR analyses using primers for ES cell-specific genes were performed (Figure 2d ). Endogenous Rex1, Nanog, Oct4, and Sox2 were expressed in all mdx-iPS (DYS-HAC) cells, comparable to the parent mdx-iPS cells and Nanog-iPS cells generated previously with four Yamanaka's factors, including c-Myc. Exogenous expressions of Klf4, Sox2, and Oct4 in most mdx-iPS (DYS-HAC) cells were lower than those of parent mdx-iPS cells, suggesting that expression of transgenes was more or less silenced after MMCT.
To determine whether the mdx-iPS (DYS-HAC) cells have the ability to differentiate into all three embryonic germ layers (endoderm, mesoderm, and ectoderm), cells were subcutaneously injected into nude mice. Transplanted mdx-iPS (DYS-HAC) gave rise to typical teratomas (n = 10), and GFP + tissues were detected in these teratomas (Supplementary Figure S2a,b) . Histological analyses showed that tumors contained all three embryonic germ layers (Supplementary Figure S2c) . FISH analyses showed that DYS-HAC was detected in 90% of cells in tumor tissues (Supplementary Figure S2d) . Immunohistochemical analyses detected the expression of human dystrophin in muscle-like tissues of teratomas derived from mdx-iPS (DYS-HAC) cells, but not in those derived from mdx-iPS cells (Figure 2e ). These data suggest that loss of dystrophin expression in mdx-derived muscle tissue was restored by transferring the DYS-HAC into mdx-iPS cells. Step 1
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). Chimeras with various forms of coat-color chimerism were obtained, and GFP + chimeric mice were used for the following analyses. The EGFP gene driven by the CAG promoter on the DYS-HAC was expressed in all tissues examined (Figure 3a) , suggesting that DYS-HAC was stably maintained in vivo. To investigate whether the tissue-specific isoform of the human dystrophin on the DYS-HAC was expressed, total RNAs from various tissues of the chimeras were analyzed by RT-PCR using three pairs of specific primers to detect human dystrophin tissue-specific transcripts. Isoforms Dp427I and Dp427m were expressed in chimeric heart and skeletal muscle, and Dp140 was expressed in chimeric brain, comparable to the human expression profile (Figure 3b) . FISH analyses showed that the DYS-HAC was detected in 50% of cells at least in the brain, liver, kidney, spleen, and skeletal muscle (Figure 3c ). This detection correlated with coat-color chimerism, and the DYS-HAC was present as an individual chromosome in chimeric tail fibroblasts (Supplementary Figure S2e,f) . Immunohistochemical analysis using a human dystrophin-specific antibody showed human dystrophin protein localized at the sarcolemmal membrane in skeletal muscle (Figure 3d ). These results suggest that isoforms of human dystrophin on the DYS-HAC were expressed in a tissuespecific manner, and the human dystrophin protein was localized at the correct locus in iPS-derived chimeric skeletal muscle. These data were consistent with the results from our previous study using chimeric mice from normal mouse ES cells with the DYS-HAC.
correction of dMd-iPs cells with dYs-HAc
Next, we attempted genetic correction of iPS cells derived from a DMD patient (Figure 1 ). We chose a DMD patient with deletion of exons 4-43 for iPS cell induction because a large deletion of this type cannot be corrected even using homologous recombination or other conventional vectors. The DYS-HAC was transferred to DMD patient-derived fibroblasts via MMCT, as we failed to directly transfer the HAC into human iPS or human ES cells due to the difficulty of cloning colonies derived from single cell following transfection or MMCT, which is an unsolved issue. The DYS-HAC was successfully transferred to DMD-fibroblasts, as shown by PCR and multiplex PCR analyses (Figure 4a and Supplementary Figure S3a) . FISH analyses showed that the DYS-HAC was present as an individual chromosome in DMD patient-derived fibroblasts (data not shown). The iPS cells were generated from the DMD-fibroblasts with the DYS-HAC using a combination of lenti viral infection with mouse Slc7a1 and retroviral infection with KLF4, SOX2, OCT4, and c-MYC, as reported previously. 6 Thirty GFP + and human ES-like DMD-iPS (DYS-HAC) cells derived from three independent DMD-fibroblast (DYS-HAC) clones were selected, and randomly selected nine clones were analyzed in the following experiments. To test the stemness of iPS cells, RT-PCR analyses using primers for ES cellspecific genes were performed (Figure 4c) . Endogenous REX1, NANOG, OCT4, and SOX2 were differentially expressed in iPS cells. Exogenous OCT4, KLF4, SOX2, and c-MYC were expressed in some iPS cells. These findings show that DMD-iPS (DYS-HAC) cells were comparable to DMD-iPS and normal human iPS cells. PCR and multiplex PCR analyses showed that the DYS-HAC was maintained in all examined iPS cells, comparable to parent DMD-fibroblast (DYS-HAC) clones (Supplementary Figure S3a,b) . FISH analyses showed that the DYS-HAC was present as an individual chromosome in the DMD-iPS (DYS-HAC) cells (Figure 4d) . To examine mitotic stability of the DYS-HAC in DMD-iPS (DYS-HAC) cells, iPS cells were cultured for about 4 months without selection. FISH analyses revealed that the DYS-HAC was independently and stably maintained in DMD-iPS (DYS-HAC) cells (Figure 4e) . These data suggest that the DYS-HAC could be maintained stably during iPS generation and even after long-term culture in vitro.
To determine whether DMD-iPS (DYS-HAC) cells could differentiate into all three embryonic germ layers, cells were injected into testes of severe combined immunodeficiency mice. Transplanted DMD-iPS (DYS-HAC) gave rise to typical teratomas (n = 12), and GFP + tissues were detected in these teratomas (Supplementary Figure S4a) . Histological analyses revealed all three embryonic germ layers in all teratomas (Supplementary Figure S4b) . FISH analyses showed that the DYS-HAC was detected in 90% of cells in tumor tissues (Supplementary  Figure S4c) . Immunohistochemical analysis showed expression of human dystrophin in muscle-like tissues of teratomas derived from DMD-iPS (DYS-HAC) cells, but not in those derived from (Figure 4f ). These data were comparable to the results of the mdx-iPS (DYS-HAC) experiments mentioned above. These data suggest that loss of dystrophin expression in DMDderived muscle tissue was restored by transferring the DYS-HAC into DMD-iPS cells.
DMD-iPS cells

dIscussIon
Previously, mouse iPS cells derived from sickle cell anemia have been corrected using the homologous recombination approach, with the model mice treated using iPS-derived hematopoietic progenitors. 9 Most recently, Fanconi anemia patient-derived iPS cells were corrected using the viral vector, and the iPS cells could give rise to hematopoietic progenitors of the myeloid and erythroid lineages, showing the correction of the disease phenotype. 24 However, genetic restoration by the homologous recombination and gene transfer using the conventional vectors, including viral and plasmid vector, cannot be applied in DMD patients with large deletions in the gene. The present results have shown the first complete genetic correction of a human genetic disorder, DMD with deletion of exon 4-43, using a novel HAC as an episomal vector. As Kimura et al. recently reported myogenic conversion from fibroblasts by transducing the inducible myogenic regulator, MyoD, the DMD-fibroblast (DYS-HAC) developed in this study may also represent a source for gene therapy. 25 To the best of our knowledge, iPS cells have been generated from human primary fibroblast populations, but not from cloned cells. 6 In this study, we could generate patient-derived genetically corrected iPS cells even from fibroblasts cloned after MMCT. Although several dystrophin isoforms cannot be expressed using previously reported vector systems, our HAC vector system containing an entire genomic dystrophin enabled isoform expressions in iPS-derived various tissues with the DYS-HAC in a tissue-specific manner. As the integrating viral vectors were used for iPS generation in this study, however, iPS induction using a nonintegrating vector system, protein introduction system, or chemical small molecules may be needed for safe gene therapy. [26] [27] [28] [29] [30] [31] [32] [33] The HAC vector may also be a promising tool for safe iPS generation: the HAC is a nonintegrating vector, and the elimination of a HAC, with a conditional centromere, from the cells can also be performed. In the MMCT methods, it is possible that host chromosomes (e.g., A9 and CHO) can be transferred along with the HAC at once. However, we have seldom observed the co-transfer of host chromosomes during MMCT (~1/100 clones). In this study, host chromosomes were not detected in mdx-iPS cells and DMDfibroblasts after MMCT (data not shown).
Furthermore, advances in efficient methods for differentiation and purification of stem cells, including ES and iPS cells, are anticipated. Barberi et al. reported engraftable skeletal myoblasts from human ES cells. 35 Darabi et al. also reported the generation of functional skeletal muscle from mouse ES cells by induction of Pax3 and the treatment of mdx mice using ES cell-derived cells. 36 Application of these methods to iPS cells combined with our HAC vector system may open a way to more sophisticated DMD gene therapies. Taken together, genetic correction of patient-specific iPS cells by MMCT of the DYS-HAC, efficient differentiation from iPS cells into muscle stem cells in vitro, and transplantation of genetically corrected autologous cells into the same patient are needed for the gene therapy of DMD (Figure 1) . Thus, stem cells derived from multiple potential sources combined with HAC-mediated gene delivery should allow safe treatment of various genetic defects, with elegant differentiation technology to come.
MAterIAls And MetHods
Cell culture. Fibroblasts from a DMD patient (GM05169) containing deletion of exons 4-43 in the dystrophin gene were obtained from Coriell Institute (Camden, NJ). Fibroblast cells were grown in α-MEM plus 15% fetal bovine serum (FBS) and 2 mmol/l L-glutamine. DMD model mice (mdx) were obtained from Charles River (Yokohama, Japan), and mouse embryonic fibroblasts (MEFs) were isolated from 13.5 days postcoitum embryos. The mdx-MEF and PLAT-E cells were grown in Dulbecco's modified Eagle's medium (Sigma, St Louis, MO) plus 10% FBS. Chinese hamster ovary (CHO) or A9 cells containing the DYS-HAC were constructed as previously described. 21 The CHO (DYS-HAC) cells were maintained in Ham's F-12 nutrient mixture (Invitrogen, Carlsbad, CA) plus 10% FBS with 8 µg/ ml blasticidin S hydrochloride (Funakoshi, Tokyo, Japan). The A9 (DYS-HAC) cells were maintained in Dulbecco's modified Eagle's medium plus 10% FBS with 4 µg/ml blasticidin S hydrochloride. The parental mdx-iPS cell line and microcell hybrid clones, mdx-iPS (DYS-HAC), were maintained on mitomycin C (Sigma)-treated Jcl:ICR (CLEA Japan, Tokyo, Japan) MEFs as feeder layers in Dulbecco's modified Eagle's medium with 18% FBS (Thermo Scientific HyClone, Yokohama, Japan), 1 mmol/l sodium pyruvate (Invitrogen), 0.1 mmol/l nonessential amino acids (Invitrogen), 0.1 mmol/l 2-mercaptoethanol (Sigma), 2 mmol/l L-glutamine (Invitrogen), and 1,000 U/ml leukemia inhibitory factor (Funakoshi). Human iPS cells were maintained on SNL (STO) feeder cells in primate ES medium (ReproCell, Tokyo, Japan) supplemented with 4 ng/ml recombinant basic fibroblast growth factor (Wako, Osaka, Japan). Mouse and human iPS cells were maintained as described previously. 5, 6 The control iPS cell line, NanogiPS (APS0001, iPS-MEF-Ng-20D-17), was obtained from the RIKEN BRC Cell Bank (Tsukuba, Japan). The SNL cell line for feeder layer was obtained from the SANGER Institute (Cambridge, UK).
Generation of iPS cells. Generation of iPS cells from mdx-MEFs was performed using a retroviral system as described previously. 5 Briefly, retroviruses were generated with Plat-E packaging cells. Three retroviruses containing Oct4, Klf4, and Sox2, were infected into mdx-MEFs. Four days after transfection, mdx-MEFs were replated at 3.5 × 10 5 cells per 100-cm dish on MEF feeder cells. The next day, medium was replaced with mouse ES cell medium. Thirteen days after infection, mouse ES-like colonies were selected up to the MEF feeder cells on 24-well plates. Generation of iPS cells from human DMD-fibroblasts was performed using the retrovirus system combined with the lentivirus system as described previously. 6 Briefly, lentivirus production for Slc7a1 expression was performed using 293T cells, and lentivirus was infected into human fibroblasts. Four retroviruses containing OCT4, KLF4, SOX2 and c-MYC were infected into Slc7al-expressing human DMD-fibroblasts. The four retroviral expression vectors were obtained from Addgene (Cambridge, MA). Six days after transfection, fibroblasts were replated at 5 × 10 4 cells per 100-cm dish on SNL feeder cells. The next day, medium was replaced with primate ES cell medium supplemented with 4 ng/ml basic fibroblast growth factor. Thirty days after transduction, human ES-like colonies were selected up to the SNL feeder cells on 24-well plates.
MMCT. MMCT was performed as described previously. 37 CHO or A9 cells containing the DYS-HAC were used as donor microcell hybrids. Briefly, mdx-iPS and DMD-fibroblast cells were fused with microcells prepared from donor hybrid CHO (DYS-HAC) or A9 (DYS-HAC) cells, and selected with blasticidin S (3 µg/ml). The transferred DYS-HAC in each line was characterized by PCR, RT-PCR, and FISH analyses.
Genomic PCR analyses. Genomic DNA was extracted from cell lines and chimeric tissue specimens using a genomic extraction kit (Gentra Systems, Minneapolis, MN), and PCR was performed using primers as follows. Primer pairs for the detection of the region of human dystrophin gene were as follows: DYS3L/3R [163 base pairs (bp)], 5′-AACAACT GAACAGCCGGTGGA-3′ and 5′-GGGGTGGTGGGTTGGATTTT-3′; DYS4L/4R (128 bp), 5′-GCAAGAGCAACAAAGTGGCCTA-3′ and 5′-AG CTTCTTCCAGCGTCCCTCA-3′; DYS5L/5R (132 bp), 5′-ACCTTCAG AACCGGAGGCAAC-3′ and 5′-AGGGACCCTCCTTCCATGACTC-3′; DYS6L/6R (170 bp), 5′-TGGAACGCATTTTGGGTTGTT-3′ and 5′-AA AACAATGCGCTGCCTCAAA-3′; DYS7L/7R (151 bp), 5′-TTTGCAT CCTTTTGGCGTGAT-3′ and 5′-AAACTCAAGCCTGCCCCACTC-3′; DYS8L/8R (155 bp), 5′-GCTGCTAGCAATGCCACGATT-3′ and 5′-GGA TGGGCTGGGAATCCATAG-3′. Primer pairs for detection of EGFP on the HAC, mouse genome (A9), and hamster genome (CHO) were as follows: EGFPL/R (479 bp), 5′-CCTGAAGTTCATCTGCACCA-3′ and 5′-TGCTCAGGTAGTGGTTGTCG-3′; Cyp3a13-5L/6R (239 bp), 5′-GC TCAGCAGGCTCAGCCCTGA-3′ and 5′-TCCAAGCCAGTAAAGGAA AGAATTAT-3′; Furin-L/R, 5′-ACTCAGAGATCCACTGCACCAGGAT CCAAGGGAGG-3′ and 5′-GCTCGAGCGGCTACACCACAGACACC ATTGTTGGCTACTGCTGCC-3′. Multiplex PCR analyses to detect the deletion of exons within human dystrophin were performed in accordance with the protocols of the manufacturer (Maxim Biotech, San Francisco, CA). CHO (DYS-HAC), A9 (DYS-HAC), HFL1, and HFL1-iPS were used as positive controls. mdx-iPS, DMD-fibroblasts, DMD-iPS, STO, CHO, and A9 cells were used as negative controls.
FISH analyses. FISH analyses were performed using either fixed metaphase or interphase spreads of each cell hybrid using digoxigenin-labeled (Roche, Basel, Switzerland) human COT-1 DNA (Invitrogen) and biotinlabeled BAC DNA (RP11-954B16, located in the dystrophin genomic region), essentially as described previously. 37 Chromosomal DNA was counterstained with DAPI (Sigma). Images were captured using the NISElements system (Nikon, Tokyo, Japan).
RT-PCR analyses. Total RNA from chimeric tissue specimens was prepared using ISOGEN (Nippon Gene, Tokyo, Japan) and purified using RNeasy columns (Qiagen, Hilden, Germany), in accordance with the manufacturer's instructions, and was then treated with RNase-free DNase I (Wako). First-strand complementary DNA (cDNA) synthesis was performed using random hexamers and SuperScript III reverse transcriptase (Invitrogen). EGFP and GAPDH were used as internal controls. Human cDNA was used as a positive control, whereas cDNA and DNA from C57BL/6 mouse Generation of chimeric mice. Chimeric mice were produced from the two mdx-iPS and three mdx-iPS (DYS-HAC) cell lines. Chimera production was performed as described previously. 37 Briefly, iPS cells were injected into blastocyst-stage embryos derived from ICR mice (CLEA Japan) and then transferred into pseudopregnant ICR females. Three chimeric mice showing 50% coat-color chimerism were used for expression analyses in various tissues. All chimeric mice used for analyses were 1-4 weeks old. All animal experiments were approved by the Institutional Animal Care and Use Committee of Tottori University.
Teratoma formation and histology. To produce teratomas, 2 × 10 6 mdx-iPS (DYS-HAC), mdx-iPS, and mdx-fibroblast cells were subcutaneously injected into CD-1 (ICR)-nu mice (Charles River), and 1 × 10 6 DMD-iPS (DYS-HAC), DMD-iPS, and DMD-fibroblast (DYS-HAC) cells were injected into testes of severe combined immunodeficiency mice (Charles River). After 5-6 weeks in the mdx-iPS series and 9-13 weeks in the DMD-iPS series, resected teratomas were fixed in 20% formalin and processed for paraffin sectioning, then stained with hematoxylin and eosin.
Immunohistochemical analyses. Formalin-fixed and paraffin-embedded specimens and OCT (optimal cutting temperature) compound-embedded frozen specimens were used for immunohistochemistry. Primary antibodies used in this study were as follows: rabbit polyclonal antibody against both human and mouse dystrophin (1:100; Lab Vision, Fremont, CA); and mouse monoclonal antibody against human dystrophin (MANDYS106, diluted 1:4; a gift from Glenn E. Morris, Keele University, Shropshire, UK). Immunoreaction was developed by using the SAB (streptavidin-biotin) peroxidase complex method with the Histofine SAB-PO Kit (Nichirei, Tokyo, Japan) for rabbit polyclonal antibody and the Histofine Mouse Stain Kit (Nichirei) for mouse monoclonal antibody, or visualized with Alexa Fluor 555 goat anti-mouse conjugate (diluted 1:1,000; Molecular Probes, Eugene, OR). Figure S1 . Characterisation of mdx-iPS. Figure S2 . Histological and FISH analyses in mdx-iPS (DYS-HAC)-derived teratoma and chimera. Figure S3 . Genomic PCR analyses in DMD-fibroblast (DYS-HAC) and DMD-iPS (DYS-HAC) cells. Figure S4 . Histological and FISH analyses in DMD-iPS (DYS-HAC)-derived teratoma.
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